PLK4 and hepatocellular carcinoma: A recent study suggested that targeting Polo-like kinase 4 (PLK4), a centrosome duplication regulator, could suppress tumor proliferation via inhibiting the cell cycle and eliciting anti-tumor immunity, with durable effect even in late-stage mouse HCC (14).